Ponatinib is a third-generation, dual Src-ABL inhibitor. It was developed using computational and structure-based design to have activity against BCR-ABL forms with mutations that convey resistance to other TKIs, in particular T315I mutation. ICLUSIG is the brand name of Ponatinib was developed by ARIAD Pharmaceuticals. for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor.[2] Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.
FDA has approved ICLUSIG (ponatinib) for for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
